- About Us
- Therapies
- Therapies
- We Are Committed to our Patients
- We Are Committed to our Patients
- Therapies
- Research
- Partnering
- Partnering
- We are Committed to Success through Partnerships
- We are Committed to Success through Partnerships
- Partnering
- Responsibility
- Media
- Media
- Latest Press Releases
- EMD Serono Expands Global Research & Development Hub in Massachusetts and Continues to Build Presence in US Pharmaceuticals Market
- EMD Serono Announces Appeals Court Decision
- EMD Serono: Phase III Trial of Cilengitide Did Not Meet Primary Endpoint in Patients With Newly Diagnosed Glioblastoma
- EMD Serono and Pfizer Announce FDA Approval of Rebif® Rebidose® (interferon beta-1a)
- Latest Press Releases
- Media
- Careers
- Careers
- Learn more about working at EMD Serono
- Learn more about working at EMD Serono
- Careers
Disclaimer
This site contains medical information that is intended for residents of the United States only and is not meant to substitute for the advice provided by a medical professional. Always consult a physician if you have health concerns. Use and access of this site is subject to the terms and conditions as set out in our Legal Statement and Privacy Policy. This site contains information that is intended for US residents only. Canadian residents should consult the EMD Serono Canada Inc. website at www.emdserono.ca for information on products and services approved in Canada
